Tandem Mobi Now Compatible with Android Smartphones
MWN-AI** Summary
Tandem Diabetes Care has recently made significant strides in its commitment to advancing diabetes management technology by enabling compatibility of its Tandem Mobi automated insulin delivery system with Android smartphones throughout the U.S. This move, highlighted in a press release, marks an important milestone as it broadens accessibility and brings the convenience of Tandem Mobi to a larger audience. John Sheridan, CEO of Tandem, emphasized that this expansion aligns with their mission to offer diverse options in diabetes technology, enhancing patient experience.
Tandem Mobi, which is celebrated as the world's smallest automated insulin delivery system, utilizes the innovative Control-IQ+ predictive algorithm, which has proven to enhance glycemic control by achieving noteworthy outcomes, such as 79% time in range on Day 1. Originally launched for iPhone models in 2024, this cutting-edge pump combines a compact design that allows for various wearing styles, including wearing it discreetly or attaching it to clothing.
The accompanying Tandem Mobi mobile app has also received positive attention. This secure application enables seamless connection between the insulin delivery system and compatible Android smartphones, enhancing patient engagement and facilitating communication between users and their healthcare providers. The app is available for download on Google Play for several compatible Android models, including Google Pixel and Samsung Galaxy series.
With FDA clearance achieved in November 2025 for the Android version of the app, Tandem Diabetes Care continues its trajectory of improving diabetes management, aiming to reduce the burden of this chronic condition. Such developments may lead to better health outcomes and overall patient satisfaction. For further details on the Tandem Mobi system, interested individuals can visit the official Tandem website.
MWN-AI** Analysis
Tandem Diabetes Care's recent announcement regarding the compatibility of its Tandem Mobi insulin delivery system with Android smartphones presents both exciting opportunities and strategic considerations for investors. The addition of Android support expands the accessibility of the Tandem Mobi to a broader user base, which may significantly enhance company revenues in the highly competitive diabetes management market.
Tandem Mobi, being the smallest automated insulin delivery system, leverages Control-IQ+ technology to optimize glucose management for its users. With reported improvements like 79% time in range and 90% overnight control, the product appeals to health-conscious consumers and healthcare professionals alike—factors that may improve market penetration and customer loyalty.
The user-friendly Tandem Mobi app facilitates greater patient engagement through better connectivity with healthcare providers. Enhanced patient satisfaction could lead to an increase in repeat purchases, recommendations, and an overall positive impact on Tandem’s brand image. As diabetes prevalence continues to rise globally, the increasing demand for effective and innovative solutions offers substantial growth potential for Tandem.
From an investment perspective, monitoring the company’s capability in executing its strategic rollouts and maintaining product quality is paramount. The technology landscape for diabetes management is rapidly evolving, and competitive pressure from emerging technologies or established players must be considered.
Tandem’s stock (TNDM) could present a compelling investment opportunity, particularly given its recent strides in product development and market expansion. However, investors should assess the overall market dynamics, including regulatory risks and broader economic conditions, before committing funds. Staying informed on quarterly performance and future guidance will be critical in navigating potential volatility in this sector.
In conclusion, Tandem Diabetes Care stands at a promising juncture with its Tandem Mobi's Android compatibility, but continued vigilance regarding market fluctuations and operational execution remains essential for prospective investors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Tandem Diabetes Care expands connected-care ecosystem by adding Android platform
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world’s smallest, durable automated insulin delivery system, 1 can now be used with compatible Android smartphones in the U.S. via the Tandem Mobi mobile app.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304073769/en/
Tandem Mobi Now Compatible with Android Smartphones in U.S.
"By expanding to Android, we’re broadening our reach to bring the benefits of Tandem Mobi to even more people living with diabetes," said John Sheridan, president and chief executive officer. "It's an exciting milestone that underscores our commitment to delivering choice in diabetes technology, enabling more people to experience the convenience and flexibility that Tandem Mobi provides.”
Tandem Mobi, the tiny pump with big control, is powered by the Control-IQ+ technology predictive algorithm. Demonstrated benefits of Control-IQ+ include:
- Day 1 improvements 2†
- 79% time in range 3‡
- 90% overnight time in range 4†
Launched with compatible iPhone models in 2024, Tandem Mobi combines best-in-class outcomes with enhanced wearability. The pump is small enough for users to wear on-body with an adhesive sleeve (sold separately), clip discreetly to their clothing, or slip into the coin pocket of their pants.
The Tandem Mobi mobile app is a secure, user-friendly mobile application designed to seamlessly pair with Tandem Mobi. It enables users to manage their diabetes directly from their personal, compatible smartphone, which now includes Android devices. The app’s intuitive interface and secure connectivity to the Tandem Source platform helps support better engagement between patients and their healthcare providers, facilitating more informed treatment decisions and improved outcomes. The U.S. Food and Drug Administration cleared the Android version of the Tandem Mobi mobile app in November 2025, which was followed by a limited release in December 2025.
The Tandem Mobi mobile app is downloadable from Google Play for compatible smartphones, including Google Pixel models 6 through 10 and Samsung Galaxy models S21 through S25.
To learn more about this expanded Tandem Mobi offering, please visit:
https://www.tandemdiabetes.com/TandemMobiAndroid
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit tandemdiabetes.com .
Follow @TandemDiabetesCare on TikTok and @TandemDiabetes on Facebook, Instagram, LinkedIn, and X.
†Studies were conducted using a t:slim X2 insulin pump with Control-IQ technology and a Dexcom G6 sensor. ‡ With optimized Correction Factor based on “rule of less than 1600.”
References
- As of Jan., 2026. Data on file, Tandem Diabetes Care.
- Beck RW, et al. Diabetes Technol Ther . 2023;25(5):329-342.
- Messer LH, Breton M. Diabetes Technol Ther . 2023;25(12):877-882.
- Breton MD, Kovatchev BP. Diabetes Technol Ther . 2021;23(9):601-608.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, the anticipated timing for the availability of the Tandem Mobi Android mobile application as well as our ability to provide the Tandem Mobi Android mobile application on the Google Play Store. These statements are subject to numerous risks and uncertainties, including our ability to continue to offer the Tandem Mobi mobile application on the Google Play Store. These and other risks are identified and described in greater detail under the “Risk Factors” heading of our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Actual results could differ materially from those anticipated or projected in the forward-looking statements. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events, or other factors.
Important Safety Information
RX ONLY. The Tandem Mobi insulin pump with interoperable technology (the pump) and Control-IQ+ technology (Control-IQ+) are intended for single patient use. The pump and Control-IQ+ are indicated for use with NovoLog or Humalog U-100 insulin. Tandem Mobi system : The Tandem Mobi insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater. Control-IQ+ technology : Control-IQ+ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold.
WARNING : Control-IQ+ technology should not be used in anyone under the age of 2 years old with type 1 diabetes or under the age of 18 years old with type 2 diabetes. It should also not be used in patients who require less than a total daily insulin dose of 5 units of insulin per day or who weigh less than 20 pounds (9 kilograms), as those are the required minimum values needed for Control-IQ+ to operate safely.
Users of the pump and Control-IQ+ must: use the insulin pump, iCGM, and all other system components in accordance with their respective instructions for use. Failure to follow these instructions for use could result in an over delivery or under delivery of insulin. This can cause hypoglycemia (low BG) or hyperglycemia (high BG) events. Visit tandemdiabetes.com/safetyinfo for additional important safety information.
© 2026 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ+, t:slim X2, Tandem Source, and Tandem Mobi are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. iPhone is a trademark of Apple Inc., registered in the U.S. and other countries. Android and Google Play are trademarks of Google LLC. All third-party marks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260304073769/en/
Media Contact:
858-366-6900
media@tandemdiabetes.com
Investor Contact:
858-366-6900
IR@tandemdiabetes.com
FAQ**
How is Tandem Diabetes Care Inc. (TNDM) planning to leverage the addition of the Android platform to increase market share and reach among diabetes patients in the U.S.?
What impact do you anticipate the Android compatibility of Tandem Mobi will have on user engagement and sales for Tandem Diabetes Care Inc. (TNDM) moving forward?
Can you discuss the implications of the FDA clearance for the Tandem Mobi mobile app on Tandem Diabetes Care Inc. (TNDM) future product development and innovation?
What strategic partnerships or marketing efforts is Tandem Diabetes Care Inc. (TNDM) pursuing to promote the new Tandem Mobi Android app and enhance patient outcomes?
**MWN-AI FAQ is based on asking OpenAI questions about Tandem Diabetes Care Inc. (NASDAQ: TNDM).
NASDAQ: TNDM
TNDM Trading
-6.67% G/L:
$21.27 Last:
659,753 Volume:
$22.12 Open:
